Connect your AI

Opus Genetics IRD Proceeds from issuance of preferred stock

Proceeds from issuance of preferred stock at other companies

Evommune EVMN

$2M—

Evolution Metals & Technologies Corp. EMAT

$5.55M—

Maze Therapeutics, Inc. Common StockMAZE

$17.7M—

HTF

Heartflow, Inc. Common StockHTFL

$42.24M—

LBR

LB Pharmaceuticals Inc Common StockLBRX

$0-100%

Gloo Holdings, Inc. GLOO

$190K—

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's proceeds from issuance of preferred stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's proceeds from issuance of preferred stock?: Opus Genetics (IRD) reported proceeds from issuance of preferred stock of $25M in Q1 2026.